MultiViVax is a consortium that has been established to develop effective vaccines against multiple lifecycle stages of Plasmodium vivax malaria
Despite a marked reduction in mortality rates, malaria remains a huge global health burden.
Malaria in humans is most commonly caused by the two parasites Plasmodium falciparum and Plasmodium vivax. Whilst the former is the more deadly of the two, prompting extensive scientific research, P. vivax is the most widely spread, responsible for a significant number of human malaria cases and increasingly recognised to be a severe form of malaria. This is highlighted by World Health Organization in the latest Malaria Vaccine Technology Roadmap, where strategic goals include the licencing of vaccines targeting both P. falciparum and P. vivax by 2030.
MultiViVax seeks to contribute to the global efforts to eradicate malaria by developing effective vaccines against multiple lifecycle stages of P. vivax.
Header image from Gething et al; A long neglected world malaria map: Plasmodium vivax endemicity in 2010; Public library of Science Neglected Tropical Disease, 6 (9):e1814 ©2012 Malaria Atlas Project